Department of Respiratory Medicine, Interstitial Lung Disease Unit, Pneumonology Molecular & Cellular Lab, Faculty of Medicine, University of Crete, Heraklion, Greece.
Faculty of Medicine, University of Crete, Heraklion, Greece.
Curr Opin Pulm Med. 2020 Sep;26(5):457-463. doi: 10.1097/MCP.0000000000000703.
To present an overview of the impact of idiopathic pulmonary fibrosis (IPF) on patients' emotional well being and quality of life (QoL).
IPF is an interstitial lung disease which causes irreversible, progressive lung scarring in a pathological pattern of usual interstitial pneumonia. The incidence of IPF is increasing at a global level, subjecting an increasing number of people to its high morbidity and risk of mortality. Diagnosis is based on a multidisciplinary team approach and the exclusion of other interstitial lung diseases. Two novel antifibrotic treatments, pirfenidone and nintedanib, were recently approved by regulatory agencies around the globe, thus providing many IPF patients with treatment options for the first time. Several other drugs have entered the investigational pipeline, including many in early-phase or late-phase clinical trials. Given the incurable and progressive nature of IPF, even with antifibrotic therapy, depression and anxiety are common among patients; these and burdensome symptoms of breathlessness, cough and fatigue are factors that impact patients' emotional well being and QoL. In addition to even more effective drugs, there is a need for psychosocial interventions and mental health support strategies focused on improving patients' QoL so they are better equipped to live with this devastating condition.
The current article highlights the effects of IPF on patients' emotional well being and QoL and offers suggestions for strategies to help patients with IPF live as well as possible in their daily lives.
介绍特发性肺纤维化（IPF）对患者情绪健康和生活质量（QoL）的影响。
IPF 是一种间质性肺疾病，导致以普通间质性肺炎为病理模式的不可逆转、进行性肺瘢痕形成。IPF 的发病率在全球范围内呈上升趋势，使越来越多的人面临其高发病率和高死亡率的风险。诊断基于多学科团队方法，并排除其他间质性肺疾病。两种新型抗纤维化药物吡非尼酮和尼达尼布最近已在全球监管机构获得批准，从而首次为许多 IPF 患者提供了治疗选择。其他几种药物已进入研究管道，包括许多处于早期或晚期临床试验阶段的药物。鉴于 IPF 的不可治愈和进行性，即使进行抗纤维化治疗，患者中也常见抑郁和焦虑；这些以及呼吸困难、咳嗽和疲劳等症状的负担会影响患者的情绪健康和 QoL。除了更有效的药物外，还需要针对改善患者 QoL 的心理社会干预和心理健康支持策略，使他们能够更好地应对这种毁灭性疾病。
本文重点介绍了 IPF 对患者情绪健康和 QoL 的影响，并提出了帮助 IPF 患者在日常生活中尽可能过上更好生活的策略建议。
